| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
|
N Engl J Med
|
2010
|
5.17
|
|
2
|
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
|
J Clin Oncol
|
2005
|
4.77
|
|
3
|
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
4.57
|
|
4
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
|
N Engl J Med
|
2012
|
4.10
|
|
5
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.59
|
|
6
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
|
J Natl Cancer Inst
|
2013
|
2.28
|
|
7
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
|
J Clin Oncol
|
2013
|
2.12
|
|
8
|
Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
|
Menopause
|
2007
|
2.04
|
|
9
|
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
|
Breast Cancer Res Treat
|
2010
|
1.65
|
|
10
|
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
|
Clin Breast Cancer
|
2010
|
1.00
|
|
11
|
What do perceived cognitive problems reflect?
|
J Support Oncol
|
2008
|
0.96
|
|
12
|
The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity.
|
Oncol Nurs Forum
|
2011
|
0.79
|
|
13
|
Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right...
|
Oncology (Williston Park)
|
2016
|
0.75
|
|
14
|
Trastuzumab as single agent therapy for HER2-positive metastatic breast cancer.
|
Onkologie
|
2010
|
0.75
|
|
15
|
Reply to V. Pitini et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
16
|
HER2 targeting in early breast cancer: more options and more questions.
|
Oncology (Williston Park)
|
2014
|
0.75
|
|
17
|
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
|
Clin Breast Cancer
|
2008
|
0.75
|